MIXED ASPERGILLUS- aspergillus niger, aspergillus repens, aspergillus oryzae, aspergillus terreus injection, solution MIXED FEA

Land: USA

Språk: engelska

Källa: NLM (National Library of Medicine)

Aktiva substanser:

ASPERGILLUS NIGER VAR. NIGER (UNII: 9IOA40ANG6) (ASPERGILLUS NIGER VAR. NIGER - UNII:9IOA40ANG6), ASPERGILLUS REPENS (UNII: SQ89E6LOME) (ASPERGILLUS REPENS - UNII:SQ89E6LOME), ASPERGILLUS FLAVUS VAR. ORYZAE (UNII: Q6Z8UK5R3G) (ASPERGILLUS FLAVUS VAR. ORYZAE - UNII:Q6Z8UK5R3G), ASPERGILLUS TERREUS (UNII: QBN8K7055X) (ASPERGILLUS TERREUS - UNII:QBN8K7055X)

Tillgänglig från:

ALK-Abello, Inc.

INN (International namn):

FRAXINUS AMERICANA POLLEN

Sammansättning:

FRAXINUS AMERICANA POLLEN 0.05 g in 1 mL

Administreringssätt:

SUBCUTANEOUS

Terapeutiska indikationer:

Hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust, molds, animal danders, various other inhalants, and in situations where the offending allergen cannot be avoided. Prior to initiation of therapy, the clinical sensitivity should be established by careful evaluation of the patient’s history confirmed by diagnostic skin testing. Hyposensitization should not be prescribed for sensitivities to allergens which can easily be avoided. A patient should not be immunized with preparations of allergens to which the patient has not demonstrated symptoms, IgE antibodies, positive skin tests, or properly controlled challenge testing. In most cases, immunotherapy is not indicated for those allergens that can be eliminated or minimized by environmental control. Patients on beta-blockers are not candidates for immunotherapy, as they can be non-responsive to beta-agonists that may be required to reverse a systemic reaction (also see WARNINGS AND ADVERSE

Produktsammanfattning:

10 mL and 50 mL, single antigens or specified mixtures, potency expressed in PNU/mL (up to and including 100,000 PNU/mL) or W/V (up to and including 1:10 W/V), aqueous or in 50% glycerin, to be diluted prior to use. 1:10 w/v short ragweed extracts contain ≥ 300 units/mL of AgE. STORAGE: To maintain stability of allergenic extracts, proper storage conditions are essential. Bulk concentrates and diluted extracts are to be stored at 2° to 8° C even during use. Bulk or diluted extracts are not to be frozen. Do not use after the expiration date shown on the vial label.

Bemyndigande status:

Biologic Licensing Application

Produktens egenskaper

MIXED ASPERGILLUS- ASPERGILLUS NIGER, ASPERGILLUS REPENS, ASPERGILLUS
ORYZAE,
ASPERGILLUS TERREUS INJECTION, SOLUTION
MIXED FEATHERS- GALLUS GALLUS FEATHER, ANAS PLATYRHYNCHOS FEATHER,
ANSER
ANSER FEATHER INJECTION, SOLUTION
MIXED MOLDS- ALTERNARIA ALTERNATA, CLADOSPORIUM SPHAEROSPERMUM,
ASPERGILLUS NIGER, ASPERGILLUS REPENS, ASPERGILLUS ORYZAE, ASPERGILLUS
TERREUS,
PENICILLIUM CHRYSOGENUM, PENICILLIUM NOTATUM INJECTION, SOLUTION
MIXED PENICILLIUM- PENICILLIUM CHRYSOGENUM, PENICILLIUM NOTATUM
INJECTION,
SOLUTION
10 TREE MIX- ACER NEGUNDO POLLEN, BETULA NIGRA POLLEN, BLACK WALNUT,
CARYA
OVATA POLLEN, FRAXINUS AMERICANA POLLEN, PLATANUS OCCIDENTALIS POLLEN,
POPULUS
DELTOIDES SUBSP. MONILIFERA POLLEN, QUERCUS RUBRA POLLEN, SALIX NIGRA
POLLEN AND
ULMUS AMERICANA POLLEN INJECTION, SOLUTION
4 WEED MIX- AMARANTHUS RETROFLEXUS POLLEN, CHENOPODIUM ALBUM POLLEN,
PLANTAGO LANCEOLATA POLLEN, XANTHIUM STRUMARIUM POLLEN INJECTION,
SOLUTION
BIRCH MIX- BETULA NIGRA, BETULA POPULIFOLIA INJECTION, SOLUTION
ALK-ABELLO, INC.
----------
THERAPEUTIC ALLERGENIC EXTRACTS- GLYCERIN PRODUCTS
DIRECTIONS FOR USE OF
THERAPEUTIC ALLERGENIC EXTRACTS
WARNING
This product is intended for use by physicians who are experienced in
the
administration of allergenic extracts and the emergency care of
anaphylaxis or for
use under the guidance of an allergy specialist.
Patients should be instructed to recognize adverse reaction symptoms
and
cautioned to contact the physician’s office if reaction symptoms
occur. As with all
allergenic extracts, severe systemic reactions may occur. In certain
individuals,
these reactions may rarely result in death. Patients should be
observed for 20 to
30 minutes following treatment, and emergency measures, as well as
personnel
trained in their use, should be immediately available in the event of
a life-threatening
reaction. Patients with unstable asthma or steroid dependent
asthmatics and
patients with underlying cardiovascular disease are at greater risk.
Adverse events
are to be reported to Med Watch (1-800-FDA-1088)